

(Formerly known as Orchid Chemicals & Pharmaceuticals Limited) Corp. Off.: Orchid Pharma Ltd., 'Orchid Towers' 313, Valluvarkottam High Road, Nungambakkam, Chennai - 600 034. India. CIN: L24222TN1992PLC022994

April 13, 2021

National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th Floor, Plot No: C/1 G - Block, Bandra - Kurla Complex Bandra (East) Mumbai - 400 051.

BSE Limited Corporate Relationship Department 1st floor, New Trading Ring Rotunda Building, P J Towers Dalal Street, Fort Mumbai - 400 001

Dear Sir/Madam

SUB: SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 Fund raising by issuance of debt securities by Large Entities

With reference to the above SEBI Circular dated November 26, 2018 in respect of fund raising by issuance of debt securities by Large Corporates (LC), we hereby submit that Orchid Pharma Limited ("the Company") does not fall under Large Corporates (LC) category as per the framework provided in the aforesaid circular.

Further, we are enclosing herewith Annexure A as required under the aforesaid circular.

Kindly take the above on your records.

Thanking you,

Yours faithfully S. L. S. Han Road Hon Road Nundymbakkam Chennal-600 034 Chief Financial Officer



Annexure A

Format of the Initial Disclosure/Annual disclosure to be made by an entity identified as a Large Corporate

Sr. No.	Particulars	Details
1	Name of the Company	Orchid Pharma Limited
2	CIN	L24222TN1992PLC022994
3	Outstanding borrowing of company as on 31st March 2021 / 31st December , as applicable (in Rs. cr)	Rs.364 Crores
4	Highest Credit Rating during the previous FY along with name of the Credit Rating Agency	CARE Ratings Limited Long term bank facilities- CARE BB+;Stable Short term bank facilities-CARE A4+
5	Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	Not Applicable

We confirm that we are **not** a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.



kioh Road Sunil Kumar Guptanungambakkam ial-600 03 Chief Financia sunilgupta@orchidpharma.com

Date: 13-04-2021

- In terms of para 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.